[go: up one dir, main page]

MA62917A1 - Composés de lactivicine, leur préparation et leur utilisation en tant qu'agents antibactériens - Google Patents

Composés de lactivicine, leur préparation et leur utilisation en tant qu'agents antibactériens

Info

Publication number
MA62917A1
MA62917A1 MA62917A MA62917A MA62917A1 MA 62917 A1 MA62917 A1 MA 62917A1 MA 62917 A MA62917 A MA 62917A MA 62917 A MA62917 A MA 62917A MA 62917 A1 MA62917 A1 MA 62917A1
Authority
MA
Morocco
Prior art keywords
compounds
activicin
preparation
antibacterial agents
antibiotics
Prior art date
Application number
MA62917A
Other languages
English (en)
Other versions
MA62917B1 (fr
Inventor
Samarendra N Maiti
Renata Jankowska
Sameeh M Salama
Original Assignee
Fedora Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fedora Pharmaceuticals Inc filed Critical Fedora Pharmaceuticals Inc
Publication of MA62917A1 publication Critical patent/MA62917A1/fr
Publication of MA62917B1 publication Critical patent/MA62917B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des composés de lactivicine de formule (i) et des sels pharmaceutiquement acceptables des composés de formule (i), les composés comprenant des antibiotiques appropriés pour être utilisés seuls ou en combinaison avec des inhibiteurs de p-lactamase et/ou d'autres antibiotiques (notamment des antibiotiques p-lactame et non p-lactame) dans le traitement ou la prévention d'infections bactériennes.
MA62917A 2021-03-31 2022-03-29 Composés de lactivicine, leur préparation et leur utilisation en tant qu'agents antibactériens MA62917B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163168406P 2021-03-31 2021-03-31
PCT/IB2022/052900 WO2022208356A1 (fr) 2021-03-31 2022-03-29 Composés de lactivicine, leur préparation et leur utilisation en tant qu'agents antibactériens

Publications (2)

Publication Number Publication Date
MA62917A1 true MA62917A1 (fr) 2024-02-29
MA62917B1 MA62917B1 (fr) 2025-11-28

Family

ID=83458148

Family Applications (1)

Application Number Title Priority Date Filing Date
MA62917A MA62917B1 (fr) 2021-03-31 2022-03-29 Composés de lactivicine, leur préparation et leur utilisation en tant qu'agents antibactériens

Country Status (16)

Country Link
US (1) US11780832B2 (fr)
EP (2) EP4685147A2 (fr)
JP (1) JP7551186B2 (fr)
KR (1) KR20230163532A (fr)
CN (1) CN117500802A (fr)
AU (1) AU2022250095B2 (fr)
CL (1) CL2023002933A1 (fr)
CO (1) CO2023013362A2 (fr)
CR (1) CR20230510A (fr)
EC (1) ECSP23080267A (fr)
IL (1) IL307344B1 (fr)
MA (1) MA62917B1 (fr)
MX (1) MX2023011616A (fr)
PE (1) PE20240149A1 (fr)
WO (1) WO2022208356A1 (fr)
ZA (1) ZA202309204B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4429660A4 (fr) * 2021-11-12 2025-09-03 Fedora Pharmaceuticals Inc Compositions pharmaceutiques comprenant des inhibiteurs de ltv-17 et de bêta-lactamase et leur utilisation en tant qu'agents antibactériens
CN118955554B (zh) * 2024-10-15 2025-08-29 浙江瑞博制药有限公司 一种取代氧杂环化合物及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252538A (en) 1984-05-21 1993-10-12 American Cyanamid Company (2-imidazolin-2-yl) fused heteropyridine compounds, intermediates for the preparation of and use of said compounds as herbicidal agents
WO1987000178A1 (fr) 1984-12-18 1987-01-15 Takeda Chemical Industries, Ltd. Derives antibiotiques nouveaux, leur procede de preparation et d'utilisation
WO1987000527A1 (fr) 1985-07-12 1987-01-29 Takeda Chemical Industries, Ltd. Composes antibacteriens, leur utilisation et procede de preparation
WO1986006380A1 (fr) * 1985-04-30 1986-11-06 Takeda Chemical Industries, Ltd. Composes antibacteriens, utilisation et preparation
EP0219923B1 (fr) 1985-04-30 1992-09-02 Takeda Chemical Industries, Ltd. Dérivés antibiotiques, leur préparation et leur application
ZA918014B (en) 1990-11-05 1992-07-29 Squibb & Sons Inc Heteroaroyl derivatives of monocyclic beta-lactam antibiotics
US5250691A (en) 1991-09-09 1993-10-05 E. R. Squibb & Sons, Inc. Heteroaryl derivatives of monocyclic beta-lactam antibiotics
PL218196B1 (pl) 2000-09-14 2014-10-31 Basilea Pharmaceutica Ag Izomery syn pochodnych kwasów 3-(heteroaryloacetamido) -2-oksoazetydyno-1-sulfonowych jako środki przeciwbakteryjne
TW200305422A (en) * 2002-03-18 2003-11-01 Shionogi & Co Broad spectrum cefem compounds
EP2308874B1 (fr) 2005-12-07 2013-01-23 Basilea Pharmaceutica AG Monobactames pontés antibiotiques utiles comme inhibiteurs de bèta-lactamase
EP2471792B1 (fr) 2009-08-28 2014-04-09 Daiichi Sankyo Company, Limited Dérivé d'acide 3-(biaryloxy)propionique
DK2646436T3 (en) 2010-11-29 2015-06-29 Pfizer monobactams
CA2859965A1 (fr) 2011-12-21 2013-06-27 Ardelyx, Inc. Agonistes de tgr5 non systemiques
US10407421B2 (en) 2016-03-07 2019-09-10 Merck Sharp & Dohme Corp Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections
WO2020018929A1 (fr) * 2018-07-20 2020-01-23 Yale University Pyrazolidinones conjuguées à des sidérophores et analogues de celles-ci
WO2020206381A1 (fr) * 2019-04-03 2020-10-08 Sutton Larry D Composés céphèmes comprenant des groupes réactifs latents et méthodes d'utilisation et procédés de fabrication de ceux-ci

Also Published As

Publication number Publication date
EP4313980A4 (fr) 2024-07-17
CA3213971A1 (fr) 2022-10-06
IL307344A (en) 2023-11-01
BR112023020056A2 (pt) 2024-01-23
IL307344B1 (en) 2026-01-01
WO2022208356A1 (fr) 2022-10-06
ECSP23080267A (es) 2024-01-31
US20220324858A1 (en) 2022-10-13
JP2024509643A (ja) 2024-03-04
MA62917B1 (fr) 2025-11-28
US11780832B2 (en) 2023-10-10
CO2023013362A2 (es) 2024-01-25
KR20230163532A (ko) 2023-11-30
PE20240149A1 (es) 2024-02-06
JP7551186B2 (ja) 2024-09-17
ZA202309204B (en) 2025-09-25
CL2023002933A1 (es) 2024-04-12
EP4685147A2 (fr) 2026-01-28
AU2022250095B2 (en) 2023-11-23
NZ804243A (en) 2024-01-26
EP4313980A1 (fr) 2024-02-07
CN117500802A (zh) 2024-02-02
CR20230510A (es) 2024-03-21
AU2022250095A1 (en) 2023-11-02
MX2023011616A (es) 2023-10-30

Similar Documents

Publication Publication Date Title
MA57825B1 (fr) Tétrahydrofuranes substitués en tant que modulateurs de canaux sodiques
MA64509B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA59373B1 (fr) [1,3]diazino[5,4-d]pyrimidines en tant qu'inhibiteurs de her2
MA59379B1 (fr) Aminothiazoles substitués en tant qu'inhibiteurs de dgkzeta pour l'activation immunitaire
RU2560846C1 (ru) Фармацевтические композиции, содержащие сулбактам и ингибитор бета-лактамазы
MA44674B1 (fr) Inhibiteurs de bromodomaine
MA31036B1 (fr) Inhibiteurs non nucleosidiques de la transcriptase inverse
MA31894B1 (fr) Composes organiques
TNSN98082A1 (fr) DERIVES SUBSTITUES EN C - 4 DE 9 - DESOXO - 9a - aza - 9a HOMOERYTHROMYCINE A.
MA31283B1 (fr) Produits dérivés de 2,3-dihydroimidazo[1,2-c]quinazoline substitués, utiles pour le traitement de troubles hyperlifératifs et de maladies associées à une angiogénèse
FR2918571B1 (fr) Compositions antibiotiques a base d'huiles essentielles prophylaxie et traitement d'infections nosocomiales
EA200100623A1 (ru) Кетолидные антибиотики
EA199901014A1 (ru) C-4"-замещенные макролидные производные
MA34655B1 (fr) Dérivés de 2,3- dihydroimidazo[1,2-c]quinazoléine substitués par un aminoalcool utiles pour traiter des troubles hyperprolifératifs et des maladies associées à l'angiogenèse
MA56883B1 (fr) Dérivés de 2-hydroxycycloalcane-1-carbamoyle
MA62917A1 (fr) Composés de lactivicine, leur préparation et leur utilisation en tant qu'agents antibactériens
CA2853152A1 (fr) Compositions et procedes pour traiter des infections vaginales et des biofilms vaginaux pathogenes
MA32764B1 (fr) Inhibiteurs de l'intégrase du vih
MA46229A (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
GT199900208A (es) Antibiòticos cetòlidos carbamato y carbazato.
MA26701A1 (fr) PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSTIONS PHARMACEUTIQUES LES CONTENANT.
EA202092579A1 (ru) Оксозамещенное соединение
BR0006301A (pt) Macrólidos antibacterianos e pró-cinéticos
MA57379B1 (fr) Modulateurs du recepteur alpha associe aux oestrogenes (err-alpha)
EA200001029A1 (ru) Производные гигромицина